• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • INT
    • US
    • FR
‘Never a Dull Moment’ Dr. Ravi Prakash Keeps Patients Front and Center

‘Never a Dull Moment’ Dr. Ravi Prakash Keeps Patients Front and Center

by Elizabeth | Jun 11, 2025 | Press Coverage

Dr. Ravi Prakash of Advocate Good Samaritan Hospital is a leader in gastroenterology and a valued member of the Cellvizio community. Dr. Prakash champions the adoption of advanced medical technology, understanding that modern tools are essential to...
Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 

Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 

by Elizabeth | Jun 5, 2025 | News

All the resolutions proposed by the Board of Directors were adopted  Paris and Boston, June 5, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser...
Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 

Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 

by Elizabeth | Jun 2, 2025 | News

Cellvizio® technology combined with AI outperforms human experts in pancreatic cyst risk stratification, a major breakthrough for patient management  Results build on new CLIMB study data recently presented at Digestive Disease Week® (DDW)1 confirming Cellvizio®’s...
Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 

Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 

by Elizabeth | May 21, 2025 | News

Ongoing Strategic Negotiations Towards a Licensing Agreement  Strong Momentum for CellTolerance: Over 1,500 Procedures Completed, New Centers of Excellence Adopting the Technology, Including a Leading U.S. Institution  Paris and Boston, May 21, 2025 – 5:45...
Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 

Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

by Elizabeth | May 20, 2025 | News

Paris and Boston, May 20, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the availability of...
« Older Entries

Articles récents

  • ‘Never a Dull Moment’ Dr. Ravi Prakash Keeps Patients Front and Center
  • Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 
  • Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 
  • Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 
  • Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}